CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Jefferies 2025 Global Healthcare Conference

Date: June 4, 2025

Fireside Chat: 11:40 AM ET

Event: Goldman Sachs 46th Annual Global Healthcare Conference

Date: June 10, 2025

Fireside Chat: 9:20 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at .

About Centessa Pharmaceuticals

is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. We also have an early-stage immuno-oncology program focused on our novel LockBody® technology platform. For more information, visit , which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
19/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fireside Chat: 9:20 AM ET Ac...

 PRESS RELEASE

Centessa Pharmaceuticals Reports Financial Results and Business Highli...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders w...

 PRESS RELEASE

Centessa Pharmaceuticals Reports Business Highlights and Financial Res...

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorde...

 PRESS RELEASE

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clin...

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), n...

 PRESS RELEASE

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025Fireside Chat: 1:00 PM ET Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: February 12, 2025Fireside Chat: 10:40 AM ET Event: TD Cowen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch